CSC(601066) 证券时报网·2024-12-12 00:21Core Insights - The core viewpoint is that the pharmaceutical sector in China is expected to see significant reforms and investment opportunities by 2025, particularly with the establishment of a diversified payment system and the introduction of new compensation structures and tiered medical services [1]. Group 1 - The reform policies in the pharmaceutical field have become normalized, with a focus on the healthcare insurance sector as a key area for incremental policy changes [1]. - The upcoming reforms in the medical field, including compensation systems and tiered diagnosis and treatment, are anticipated to enter a "deep water zone," aligning with expectations [1]. - China's pharmaceutical industry is gradually gaining international recognition, with marginal improvements expected in certain sub-sectors and the commencement of industry consolidation [1]. Group 2 - It is recommended to focus on new growth areas such as innovation, international expansion, and marginal changes, as well as opportunities arising from industry consolidation [2].